<ѻýҕl>Adding Isatuximab to Standard Backbone Improves Outcomes in Multiple Myelomaѻýҕl> Two trials show positive outcomes Jun 04, 2024
Industry Clinic • Ad Insights <ѻýҕl>What Will It Take to Deliver Both Health & Care in Oncology?ѻýҕl> Jun 04, 2024
<ѻýҕl>Blenrep-Based Regimen Yields PFS Benefit in Relapsed/Refractory Myelomaѻýҕl> Second belantamab mafodotin-containing triplet to show potency in this setting Jun 02, 2024
<ѻýҕl>Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exerciseѻýҕl> News, features, and commentary about cancer-related issues May 10, 2024
<ѻýҕl>Ending Oncology's Toxic Relationship With High Chemotherapy Dosesѻýҕl> Optimizing doses can improve patient outcomes and lower costs May 10, 2024
<ѻýҕl>Quadruplet Shows 'Excellent Activity' in Myeloma Patients Who Defer HSCTѻýҕl> ORR reaches 90% with isatuximab plus KRd in newly diagnosed disease Apr 26, 2024
<ѻýҕl>FDA Approves Earlier Use of CAR-T Products for Myelomaѻýҕl> Carvykti and Abecma move to second- and third-line, respectively Apr 08, 2024
<ѻýҕl>High Response Rate in R/R Multiple Myeloma With Bispecific Antibodyѻýҕl> ORR of 71% that deepened over time and favorable safety profile with linvoseltamab Apr 08, 2024
<ѻýҕl>Chemo and Heart Disease; Flawed Lung Cancer Screening; New Vax Recommendationsѻýҕl> News, features, and commentary about cancer-related issues Mar 29, 2024
<ѻýҕl>FDA Panel Gives Thumbs Up to Earlier Use of CAR T-Cell Therapy in Multiple Myelomaѻýҕl> Cilta-cel, ide-cel win support despite concerns about early mortality risk Mar 16, 2024
<ѻýҕl>Early Death Risk Muddies Risk-Benefit Assessment of CAR-T Therapies for Myelomaѻýҕl> FDA advisory panel to weigh the evidence for cilta-cel, ide-cel in day-long meeting Mar 14, 2024
<ѻýҕl>A Blenrep Comeback? Cancer Vaccine for Dogs; U.K. Snubs Enhertuѻýҕl> News, features, and commentary about cancer-related issues Mar 07, 2024
<ѻýҕl>Toxic Gas That Sterilizes Medical Devices Prompts Safety Rule Updateѻýҕl> The EPA is set to take action after public outcry Mar 03, 2024
<ѻýҕl>Taking Control of the Cancer Journeyѻýҕl> Kathy Giusti gives patients and healthcare workers advice for navigating cancer treatment Mar 02, 2024 podcast
<ѻýҕl>Amy Schumer's Diagnosis; FDA Yanks Cancer Drug; Nursing Student Murderedѻýҕl> Health news and commentary from around the Web gathered by ѻýҕl staff Feb 26, 2024
<ѻýҕl>Transforming Shots Into Pills; 'Tip of the Iceberg' for TILs? Food Additives Warningѻýҕl> News, features, and commentary about cancer-related issues Feb 23, 2024
<ѻýҕl>Elotuzumab Misses Mark Again as Frontline Treatment for Multiple Myelomaѻýҕl> No PFS benefit from adding the monoclonal antibody to standard therapy Feb 20, 2024
<ѻýҕl>Pulled Myeloma Drug May Have a Role in Treating the Disease After Allѻýҕl> Belantamab mafodotin boosts PFS by nearly 2 years when combined with bortezomib, dexamethasone Feb 07, 2024
<ѻýҕl>When a Revolutionary Cancer Treatment Causes Cancerѻýҕl> The potential benefits of CAR T-cell therapies still far outweigh the risks Jan 27, 2024
<ѻýҕl>How Can Cancer Risk Be Cut in Communities Exposed to Toxins?ѻýҕl> Group outlines plan to bring the latest testing and treatment to medically underserved minorities Jan 25, 2024
<ѻýҕl>CAR-T Investigation: FDA Leaders Detail Decision on Cancer Risk Warningѻýҕl> Post-treatment cases grow to 22 since products' initial approvals Jan 24, 2024
<ѻýҕl>FDA Calls for New Boxed Warning on All CAR-T Productsѻýҕl> Most serious warning would alert patients, providers on potential risk for secondary malignancies Jan 23, 2024
<ѻýҕl>Daratumumab Added to Standard Therapy Improves PFS in Multiple Myelomaѻýҕl> Subcutaneous administration of the anti-CD38 antibody also made for easier dosing Jan 04, 2024
<ѻýҕl>Can JAK Inhibition Help Overcome Lenalidomide Resistance in Myeloma?ѻýҕl> Early-phase experience with ruxolitinib suggests potential role in relapsed/refractory disease Dec 21, 2023 video
<ѻýҕl>Why Some Myeloma Patients Refuse Stem Cell Transplantѻýҕl> Study shows the various factors behind refusal of autologous stem cell transplantation Dec 15, 2023 video
<ѻýҕl>Four Drugs Top Three for Upfront Treatment of Multiple Myelomaѻýҕl> Adding anti-CD38 antibodies boosts response and PFS, but timing, sequencing, cost questioned Dec 13, 2023
<ѻýҕl>Benefits of Myeloma Regimens in the Real World Fall Well Short of Trialsѻýҕl> Survival 75% worse compared with outcomes seen in registrational studies Dec 10, 2023
<ѻýҕl>Let's Talk Drug Prices; Restoring the Sense of Touch; Learning From Tumors in a Dishѻýҕl> News, features, and commentary about cancer-related issues Dec 01, 2023
<ѻýҕl>FDA Investigating 'Serious Risk' of Malignancy After CAR-T Therapyѻýҕl> Applies to all approved therapies, but benefits still outweigh risks, agency says Nov 28, 2023
<ѻýҕl>Vitamin D for Neuropathy; Good & Bad News for CAR-T; New Labeling for Surgical Meshѻýҕl> News, features, and commentary about cancer-related issues Nov 10, 2023
<ѻýҕl>Wearables as Cancer Monitors; No China Price Break; Cancer Mystery in Appalachiaѻýҕl> News, features, and commentary about cancer-related issues Nov 03, 2023
<ѻýҕl>Quad Regimen for High-Risk Myeloma Produces High Rates of Durable MRD Negativityѻýҕl> Two-thirds of transplant-eligible patients met endpoint with isatuximab/KRd Oct 19, 2023
<ѻýҕl>Lonely Cancer Deaths; Virtual Reality for Pain; 3D Models May Improve Treatmentѻýҕl> News, features, and commentary about cancer-related issues Oct 19, 2023
<ѻýҕl>Chemo Shortage: 'Paycheck to Paycheck'; Cancer Blood Test Shines; Struggling to Liveѻýҕl> News, features, and commentary about cancer-related issues Oct 06, 2023
<ѻýҕl>IV Immunoglobulin May Cut Infection Risk of Anti-BCMA Agents for Myelomaѻýҕl> Small retrospective study finds fewer severe infections during periods of replacement therapy Sep 29, 2023
<ѻýҕl>Cancer Drug Shortages for Kids; Pharma Agrees to Price Talks; Catch-Up on Screeningѻýҕl> News, features, and commentary about cancer-related issues Sep 28, 2023
<ѻýҕl>Stem-Cell Mobilization Booster Wins FDA Approval for Multiple Myelomaѻýҕl> Motixafortide plus filgrastim increased adequate harvest rate from 9.5% to 67.5% Sep 11, 2023
<ѻýҕl>Microdevices for Glioma; Cervical Adenocarcinoma Test; Language Gaps and Cancer Careѻýҕl> News, features, and commentary about cancer-related issues Sep 07, 2023
<ѻýҕl>Novel Oral Tx Shows Early Promise in Relapsed/Refractory Myelomaѻýҕl> Mezigdomide led to 41% response rate in heavily pretreated patients Aug 30, 2023
<ѻýҕl>Nurse Suspected of Poisoning; Hospital Mask Mandates Return; Congressman's Cancer Dxѻýҕl> Health news and commentary from around the Web gathered by ѻýҕl staff Aug 30, 2023